IRIS Accounts Production v25.3.0.601 06833255 Board of Directors 1.4.24 30.9.25 30.9.25 false true false false true false Ordinary shares 1.00000 Ordinary shares 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 06833255 2024-03-31 06833255 2025-09-30 06833255 2024-04-01 2025-09-30 06833255 2023-03-31 06833255 2023-04-01 2024-03-31 06833255 2024-03-31 06833255 ns15:EnglandWales 2024-04-01 2025-09-30 06833255 ns14:PoundSterling 2024-04-01 2025-09-30 06833255 ns10:Director1 2024-04-01 2025-09-30 06833255 ns10:PrivateLimitedCompanyLtd 2024-04-01 2025-09-30 06833255 ns10:SmallEntities 2024-04-01 2025-09-30 06833255 ns10:AuditExemptWithAccountantsReport 2024-04-01 2025-09-30 06833255 ns10:SmallCompaniesRegimeForDirectorsReport 2024-04-01 2025-09-30 06833255 ns10:SmallCompaniesRegimeForAccounts 2024-04-01 2025-09-30 06833255 ns10:FullAccounts 2024-04-01 2025-09-30 06833255 ns10:OrdinaryShareClass1 2024-04-01 2025-09-30 06833255 ns10:Director2 2024-04-01 2025-09-30 06833255 ns10:RegisteredOffice 2024-04-01 2025-09-30 06833255 ns5:CurrentFinancialInstruments 2025-09-30 06833255 ns5:CurrentFinancialInstruments 2024-03-31 06833255 ns5:ShareCapital 2025-09-30 06833255 ns5:ShareCapital 2024-03-31 06833255 ns5:RetainedEarningsAccumulatedLosses 2025-09-30 06833255 ns5:RetainedEarningsAccumulatedLosses 2024-03-31 06833255 ns5:FurnitureFittings 2024-03-31 06833255 ns5:FurnitureFittings 2024-04-01 2025-09-30 06833255 ns5:FurnitureFittings 2025-09-30 06833255 ns5:FurnitureFittings 2024-03-31 06833255 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-09-30 06833255 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-03-31 06833255 ns10:OrdinaryShareClass1 2025-09-30

REGISTERED NUMBER: 06833255 (England and Wales)

| UNAUDITED FINANCIAL STATEMENTS |

| FOR THE PERIOD |

| 1 APRIL 2024 TO 30 SEPTEMBER 2025 |

| FOR |

| RAY BIOSCIENCE CONSULTING LTD |

RAY BIOSCIENCE CONSULTING LTD (REGISTERED NUMBER: 06833255)

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE PERIOD 1 APRIL 2024 TO 30 SEPTEMBER 2025

| Page |

Company Information | 1 |

Accountants' Report | 2 |

Statement of Financial Position | 3 |

Notes to the Financial Statements | 4 |  | to |  | 6

RAY BIOSCIENCE CONSULTING LTD

COMPANY INFORMATION

FOR THE PERIOD 1 APRIL 2024 TO 30 SEPTEMBER 2025

| DIRECTORS: | Dr K P Ray

| Mrs J H Ray

| REGISTERED OFFICE: | First Floor North

| 40 Oxford Road

| High Wycombe

| Buckinghamshire

| HP11 2EE

| REGISTERED NUMBER: | 06833255 (England and Wales)

| ACCOUNTANTS: | Seymour Taylor Limited

| First Floor North

| 40 Oxford Road

| High Wycombe

| Buckinghamshire

| HP11 2EE

ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS

ON THE UNAUDITED FINANCIAL STATEMENTS OF

RAY BIOSCIENCE CONSULTING LTD

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Statement of Financial Position. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Ray Bioscience Consulting Ltd for the period ended 30 September 2025 which comprise the Income Statement, Statement of Financial Position, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of Ray Bioscience Consulting Ltd, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Ray Bioscience Consulting Ltd and state those matters that we have agreed to state to the Board of Directors of Ray Bioscience Consulting Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Ray Bioscience Consulting Ltd and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Ray Bioscience Consulting Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Ray Bioscience Consulting Ltd. You consider that Ray Bioscience Consulting Ltd is exempt from the statutory audit requirement for the period.

We have not been instructed to carry out an audit or a review of the financial statements of Ray Bioscience Consulting Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Seymour Taylor Limited

First Floor North

40 Oxford Road

High Wycombe

Buckinghamshire

HP11 2EE

15 October 2025

RAY BIOSCIENCE CONSULTING LTD (REGISTERED NUMBER: 06833255)

STATEMENT OF FINANCIAL POSITION

30 SEPTEMBER 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 4 | - |  | 242 |  |

CURRENT ASSETS

Debtors | 5 | 10,306 |  | 2,064 |  |

Cash at bank | - |  | 28,261 |  |

10,306 |  | 30,325 |  |

CREDITORS

Amounts falling due within one year | 6 | - |  | 11,550 |  |

NET CURRENT ASSETS | 10,306 |  | 18,775 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 10,306 |  | 19,017 |  |

CAPITAL AND RESERVES

Called up share capital | 7 | 100 |  | 100 |  |

Retained earnings | 10,206 |  | 18,917 |  |

SHAREHOLDERS' FUNDS | 10,306 |  | 19,017 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 30 September 2025.

The members have not required the company to obtain an audit of its financial statements for the period ended 30 September 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 15 October 2025 and were signed on its behalf by:

Dr K P Ray - Director

RAY BIOSCIENCE CONSULTING LTD (REGISTERED NUMBER: 06833255)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD 1 APRIL 2024 TO 30 SEPTEMBER 2025

1. | STATUTORY INFORMATION

| Ray Bioscience Consulting Limited is a private company limited by shares and incorporated in England and Wales. The address of the company's registered office is First Floor North, 40 Oxford Road, High Wycombe, Buckinghamshire, HP11 2EE. The registered number is 06833255.

| The presentation currency of these financial statements is Sterling (£), being the currency of the primary economic market in which the entity operates (its functional currency). All amounts in these financial statements have been rounded to the nearest pound unless stated otherwise.

| The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| These financial statements have not been prepared on a going concern basis and have instead been prepared on the break up basis. The company is not considered a going concern as this is the final period of account prior to the company undertaking a voluntary liquidation.

| Turnover

| Turnover is measured at the fair value of consideration received or receivable for services provided, net of value added tax.

| Tangible fixed assets

| Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses.

| Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimate useful life:

| Fixtures and fittings |  | - |  | straight line over 3 years |  |

| Depreciation methods, useful lives and residual values are reviewed if there is an indication of a significant change since the last annual reporting date in the pattern by which the company expects to consume an asset's future economic benefits.

| The company assesses at each reporting date whether tangible fixed assets are impaired.

| Taxation

| Tax on the profit or loss for the year comprises current and deferred tax. Tax is recognised in the income statement except to the extent that it relates to items recognised directly in equity or other comprehensive income, in which case it is recognised directly in equity or other comprehensive income.

| Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the statement of financial position date, and any adjustment to tax payable in respect of previous years.

RAY BIOSCIENCE CONSULTING LTD (REGISTERED NUMBER: 06833255)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE PERIOD 1 APRIL 2024 TO 30 SEPTEMBER 2025

2. | ACCOUNTING POLICIES - continued

| Deferred tax

| Deferred tax is provided on timing differences which arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in the financial statements. Differences between accumulated depreciation and tax allowances for the cost of a fixed asset, if and when all conditions for retaining the tax allowances have been met, are not provided for. Deferred tax is not recognised on permanent differences arising because certain types of income or expense are non-taxable or are disallowable for tax or because certain tax charges or allowances are greater or smaller than the corresponding income or expense.

| Deferred tax is measured at the tax rate that is expected to apply to the reversal of the related difference, using tax rates enacted or substantively enacted at the statement of financial position date. Deferred tax balances are not discounted.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Defined contribution pension scheme

| The company operates a defined contribution pension scheme for the benefit of its employees. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

| Financial instruments

| The company has applied the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Instrument Issues" of FRS 102 to its financial statements.

| Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the period was 2 (2024 - 2 ) .

RAY BIOSCIENCE CONSULTING LTD (REGISTERED NUMBER: 06833255)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE PERIOD 1 APRIL 2024 TO 30 SEPTEMBER 2025

4. | TANGIBLE FIXED ASSETS

| Fixtures

| and

| fittings

£ |

| COST

| At 1 April 2024 | 3,071 |  |

| Disposals | (3,071 | ) |

| At 30 September 2025 | - |  |

| DEPRECIATION

| At 1 April 2024 | 2,829 |  |

| Charge for period | 242 |  |

| Eliminated on disposal | (3,071 | ) |

| At 30 September 2025 | - |  |

| NET BOOK VALUE

| At 30 September 2025 | - |  |

| At 31 March 2024 | 242 |  |

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | - |  | 1,500 |  |

| Other debtors | 10,306 |  | 564 |  |

10,306 |  | 2,064 |  |

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Taxation and social security | - |  | 1,006 |  |

| Other creditors | - |  | 10,544 |  |

- |  | 11,550 |  |

7. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 100 | Ordinary shares | £1 | 100 |  | 100 |  |